1887

Abstract

Patients with interstitial lung disease (ILD) who subsequently develop a viral infection have high rates of morbidity and mortality.

Few large-scale epidemiological studies have investigated potential prognostic factors for morbidity and mortality in this patient group.

To evaluate the risk factors for morbidity and mortality in hospitalized patients with ILD and viral infection, as well as the clinical characteristics.

This retrospective cohort study included patients with ILD who were hospitalized for a viral infection in two tertiary academic hospitals in China, between 1 January 2013 and 31 December 2019. We analysed the prevalence of comorbidities, clinical characteristics, 30 day mortality rates, and prognostic risk factors.

A total of 282 patients were included; 195 and 87 were immunocompromised and immunocompetent, respectively. The most common underlying interstitial diseases were idiopathic pulmonary fibrosis (42.9 %) and connective tissue disease (36.9 %). The 30 day mortality rate was 20.6 %. During the influenza season, an increase in influenza virus (IFV) (25.7 %), respiratory syncytial virus (14.9 %) and cytomegalovirus (CMV) (11.3 %) cases was observed in the immunocompromised group. The most frequently detected virus in the immunocompetent group was IFV (44.8 %), followed by respiratory syncytial virus (11.5 %), and human rhinovirus (9.2 %). During the non-influenza season, CMV (34.4 %) was the main virus detected in the immunocompromised group. The 30 day mortality rates of non-IFV patients were higher than those of IFV patients. Older age (>60 years), respiratory failure, persistent lymphocytopenia, invasive mechanical ventilation and non-IFV virus infection were significantly associated with increased 30 day mortality.

Patients with ILD who develop viral infection have high rates of morbidity and mortality, which are associated with increased age (>60 years), respiratory failure, mechanical ventilation, persistent lymphocytopenia and non-IFV virus infection. These risk factors should be carefully considered when determining treatment strategies for this patient population.

Funding
This study was supported by the:
  • beijing science and technology commission key project (Award D151100002115004)
    • Principle Award Recipient: LijuanLi
  • the ministry of science and technology support program (Award 2015BAI12B11)
    • Principle Award Recipient: LijuanLi
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001449
2021-11-05
2021-12-04
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/11/jmm001449.html?itemId=/content/journal/jmm/10.1099/jmm.0.001449&mimeType=html&fmt=ahah

References

  1. Saraya T, Kimura H, Kurai D, Tamura M, Ogawa Y et al. Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases. Respir Med 2018; 136:88–92 [View Article] [PubMed]
    [Google Scholar]
  2. Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010; 15:909–917 [View Article] [PubMed]
    [Google Scholar]
  3. Ryerson CJ, Collard HR. Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med 2014; 20:436–441 [View Article] [PubMed]
    [Google Scholar]
  4. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008; 19:227–235 [View Article] [PubMed]
    [Google Scholar]
  5. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH et al. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis. Chest 2016; 149:1205–1214 [View Article] [PubMed]
    [Google Scholar]
  6. Weng D, Chen XQ, Qiu H, Zhang Y, Li QH et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm 2019; 2019:5160694 [View Article] [PubMed]
    [Google Scholar]
  7. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An International Multicenter Study. Am J Respir Crit Care Med 2020; 202:1656–1665 [View Article] [PubMed]
    [Google Scholar]
  8. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636–643 [View Article] [PubMed]
    [Google Scholar]
  9. Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC et al. The interstitial lung disease multidisciplinary meeting: a position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology 2017; 22:1459–1472 [View Article] [PubMed]
    [Google Scholar]
  10. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012; 16:R141 [View Article] [PubMed]
    [Google Scholar]
  11. Kwok CS, Loke YK, Woo K, Myint PK. Risk prediction models for mortality in community-acquired pneumonia: a systematic review. BioMed Res Int 2013; 2013:504136 [View Article] [PubMed]
    [Google Scholar]
  12. Schauwvlieghe A, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6:782–792 [View Article] [PubMed]
    [Google Scholar]
  13. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1–e60 [View Article] [PubMed]
    [Google Scholar]
  14. Guo F, Chen Y, Yang SL, Xia H, Li XW et al. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: A retrospective study of two centers in China. PLOS ONE 2014; 9:e101943 [View Article] [PubMed]
    [Google Scholar]
  15. Vannella KM, Moore BB. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2008; 1:2 [View Article] [PubMed]
    [Google Scholar]
  16. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32:170–174 [View Article] [PubMed]
    [Google Scholar]
  17. Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res 2014; 15:109 [View Article] [PubMed]
    [Google Scholar]
  18. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:1698–1702 [View Article] [PubMed]
    [Google Scholar]
  19. Keyvani H, Moghoofei M, Bokharaei-Salim F, Mostafaei S, Javad Mousavi SA et al. Prevalence of respiratory viruses in Iranian patients with idiopathic pulmonary fibrosis. J Med Microbiol 2017; 66:1602–1606 [View Article] [PubMed]
    [Google Scholar]
  20. Zhou F, Wang Y, Liu Y, Liu X, Gu L et al. Disease severity and clinical outcomes of community acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicenter prospective registry study from CAP-China Network. Eur Respir J 2019; 54:1802406 [View Article] [PubMed]
    [Google Scholar]
  21. Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J et al. Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season. Open Forum Infect Dis 2014; 1:ofu086 [View Article] [PubMed]
    [Google Scholar]
  22. Bjarnason A, Westin J, Lindh M, Andersson LM, Kristinsson KG et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open Forum Infect Dis 2018; 5:ofy010 [View Article] [PubMed]
    [Google Scholar]
  23. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM et al. Rates of hospitalizations for respiratory syncytial virus, human Metapneumovirus, and influenza virus in older adults. J Infect Dis 2012; 206:56–62 [View Article] [PubMed]
    [Google Scholar]
  24. Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014; 8:347–352 [View Article] [PubMed]
    [Google Scholar]
  25. Ackerson B, Tseng HF, LS S, Solano Z, Slezak J et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis 2019; 69:197–203 [View Article] [PubMed]
    [Google Scholar]
  26. van Asten L, van den Wijngaard C, van Pelt W, van de Kassteele J, Meijer A et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, Norovirus, and parainfluenza in elderly persons. J Infect Dis 2012; 206:628–639 [View Article] [PubMed]
    [Google Scholar]
  27. Ngai JJ, Chong KL, Oli Mohamed S. Cytomegalovirus retinitis in primary immune deficiency disease. Case Rep Ophthalmol Med 2018; 2018:8125806 [View Article] [PubMed]
    [Google Scholar]
  28. Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr 2016; 4: [View Article] [PubMed]
    [Google Scholar]
  29. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016; 194:265–275 [View Article] [PubMed]
    [Google Scholar]
  30. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356–363 [View Article] [PubMed]
    [Google Scholar]
  31. Guo L, Wei D, Zhang X, Wu Y, Li Q et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA Score. Front Microbiol 2019; 10:2752 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001449
Loading
/content/journal/jmm/10.1099/jmm.0.001449
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error